The turnover reflects consolidated figures following an approval from the Andhra Pradesh High Court for the merger of Cheminor Drugs with it. However, the figures exclude the sales of American Remedies Ltd, a company release said. The bulk active business, which contributed 50 per cent to the total revenues during the quarter, grew by 27 per cent to Rs 109.05 crore over the corresponding quarter last year. However, bulk active sales in India declined by three per cent on account of the falling prices of major molecules including ciprofloxacin, omeprazole, sparfloxacin, ranitidine and domperidone in particular. However, the decline was adequately compensated by an improved 48 per cent growth in the interantional arena in bulk actives, the release added. The finished dosage segment, which contributed 46 per cent to the revenues in the third quarter, surged by 25 per cent to Rs 99.82 crore over the corresponding quarter, the release said. The Durgs Controller has cleared the Investigational New Drug (IND)application filed by Dr Reddy's Research Foundation (DRF) for conducting phase I clincial trials on its anti-cancer compound.